
    
      Total 720 subjects are divided into two groups and treated separately according to the HCV
      genotypeï¼ˆgenotype 2,3 and non-genotype 2,3). With 2:1 ratio between experimental group and
      positive-control group (Peginterferon alfa-2a (Pegasys) plus RBV), 216 subjects for genotype
      2,3 and 504 subjects for non-genotype2,3 will be enrolled. Accordingly, PEG-IFN-SA once
      weekly and RBV twice a day (bid) are given for 24 weeks and 48 weeks respectively to the HCV
      genotype 2,3 and the HCV non-genotype 2,3 .
    
  